Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

severe hypertriglyceridemia

- PMLiVE

Valneva to compare its COVID-19 vaccine candidate to AstraZeneca’s jab

Phase 3 trial will test Valneva’s vaccine candidate against Vaxzevria in approximately 4,000 participants

- PMLiVE

UPDATE: US pauses rollout of J&J’s COVID-19 vaccine amid reports of rare blood clots

An advisory committee to the CDC recommended extending the pause in the US to review additional data

- PMLiVE

UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval

MHRA is looking "very closely" at reports of adverse reactions to coronavirus vaccines

- PMLiVE

AZ showcases data for next-generation PARP inhibitor AZD5305

Early preclinical data presented at virtual American Association of Cancer Research meeting

- PMLiVE

New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement

Regulators in Canada and Germany have reportedly placed new restrictions on vaccine

- PMLiVE

Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine

Early-stage trial will enrol 30 healthy volunteers aged 18-40

- PMLiVE

EMA updates product information for AZ COVID-19 vaccine

PRAC reaffirms opinion that AZ vaccine's efficacy outweighs very rare likelihood of developing a blood clotting disorder

- PMLiVE

AZ publishes primary analysis for COVID-19 vaccine, showing slightly lower efficacy of 76%

AZ previously announced vaccine efficacy of 79% in US-based trial

- PMLiVE

Efficacy data from US trial for AZ/Oxford vaccine raises concerns over possible ‘incomplete view’

AZ will engage ‘immediately’ with DSMB to share primary analysis with up-to-date efficacy data

- PMLiVE

AZ/Oxford COVID-19 vaccine hits primary efficacy endpoint in US-based trial

Specific review of thrombotic events found no increased risk of thrombosis associated with vaccine

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

- PMLiVE

FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

BMS gained the rights to mavacamten as part of its acquisition of MyoKardia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links